Evidence map›Paper›PMID 37409563›Full record

ArticleeLife2023

Conditional deletion of neurexins dysregulates neurotransmission from dopamine neurons.

Charles Ducrot, Gregory de Carvalho, Benoît Delignat-Lavaud, Constantin V L Delmas, Priyabrata Halder, Nicolas Giguère, Consiglia Pacelli, Sriparna Mukherjee, Marie-Josée Bourque, Martin Parent and 2 more

Abstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Charles DucrotDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Canada.ORCID 0000-0002-5451-1610
Gregory de CarvalhoDepartment of Anatomy and Neurobiology, School of Medicine, University of California, Irvine, Irvine, United States.ORCID 0000-0002-9179-7697
Benoît Delignat-LavaudDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Canada.ORCID 0000-0003-4680-9115
Constantin V L DelmasCERVO Brain Research Centre, Department of Psychiatry and Neurosciences, Faculty of Medicine, Université Laval, Quebec, Canada.
Priyabrata HalderDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Canada.
Nicolas GiguèreDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Canada.
Consiglia PacelliDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.ORCID 0000-0003-4915-5823
Sriparna MukherjeeDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Canada.ORCID 0000-0002-1299-4343
Marie-Josée BourqueDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Canada.
Martin ParentCERVO Brain Research Centre, Department of Psychiatry and Neurosciences, Faculty of Medicine, Université Laval, Quebec, Canada.ORCID 0000-0002-0868-1010
Lulu Y ChenDepartment of Anatomy and Neurobiology, School of Medicine, University of California, Irvine, Irvine, United States.ORCID 0000-0002-8873-3481
Louis-Eric TrudeauDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Canada.ORCID 0000-0003-4684-1377

Funding

CIHR MOP106556
6 · The paper itself

Abstract

Midbrain dopamine (DA) neurons are key regulators of basal ganglia functions. The axonal domain of these neurons is highly complex, with a large subset of non-synaptic release sites and a smaller subset of synaptic terminals from which in addition to DA, glutamate or GABA are also released. The molecular mechanisms regulating the connectivity of DA neurons and their neurochemical identity are unknown. An emerging literature suggests that neuroligins, trans-synaptic cell adhesion molecules, regulate both DA neuron connectivity and neurotransmission. However, the contribution of their major interaction partners, neurexins (Nrxns), is unexplored. Here, we tested the hypothesis that Nrxns regulate DA neuron neurotransmission. Mice with conditional deletion of all Nrxns in DA neurons (DAT::NrxnsKO) exhibited normal basic motor functions. However, they showed an impaired locomotor response to the psychostimulant amphetamine. In line with an alteration in DA neurotransmission, decreased levels of the membrane DA transporter (DAT) and increased levels of the vesicular monoamine transporter (VMAT2) were detected in the striatum of DAT::NrxnsKO mice, along with reduced activity-dependent DA release. Strikingly, electrophysiological recordings revealed an increase of GABA co-release from DA neuron axons in the striatum of these mice. Together, these findings suggest that Nrxns act as regulators of the functional connectivity of DA neurons.

Indexed as

Central Nervous System StimulantsDopaminergic NeuronsAnimalsgamma-Aminobutyric AcidMicePresynaptic TerminalsSynaptic TransmissionCentral Nervous System Stimulantsgamma-Aminobutyric Acidco-transmissiondopamineGABAmouseneurexinsneurosciencesynaptic terminals

Identifiers

PMID37409563
PMCPMC10409506

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.